How Psychedelics Help People Who Are Treatment-Resistant

Psychedelic culture emerged in the 1960s, characterized by the use of psychedelic drugs, art, music, and fashion. The use of these drugs was believed to expand consciousness and enhance creativity plus self-exploration. Psychedelic experiences were frequently described as spiritual, mystical, or transcendental, and thought to offer new ways of making sense of the world and one’s place in it.

In recent years, there has been a resurgence of interest in psychedelics. The resurgence is for their potential therapeutic benefits in treating mental health disorders such as anxiety and depression. It is also for their primary role in promoting personal growth and spiritual evolution. Nonetheless, it is important to note that the use of psychedelics can also carry risks and should only be used under the guidance of a trained professional in a safe and controlled setting.

Understanding Treatment Resistance

Treatment resistance refers to a phenomenon where a patient’s medical condition fails to respond to standard treatments. This can occur in various medical conditions such as cancer, mental disorders, and infections.

Below are some key points to explain what treatment resistance stands for:

·       Failure or inability to respond to treatment: Treatment resistance is characterized by the failure of a patient’s medical condition to respond to standardized treatments. This means that the patient may not experience improvement in symptoms, despite receiving the recommended course of treatment.

·       Persistence of physical symptoms: Patients who are treatment-resistant may continue to experience symptoms that are debilitating or life-threatening, despite receiving multiple rounds of treatment. This can cause significant distress and frustration for both the patient and their healthcare providers.

·       Factors that add-on to treatment resistance: There are various factors that can contribute to treatment resistance, including genetic factors, disease severity, medication adherence, and comorbidities. Additionally, certain medical conditions may be inherently more difficult to treat. Conditions such as cancers metastasized or mental illnesses that have become chronic comprise these.

·       Available options for treatment-resistant conditions: For patients with treatment-resistant conditions, there may be alternative treatment options available. These can include clinical trials, experimental treatments, or off-label use of medications. In some cases, complementary therapies such as acupuncture, massage, psychedelic or meditation may also be helpful in managing symptoms.

·       Outcome of treatment on patients: Treatment resistance can have a significant impact on patient outcomes, both in terms of quality of life and overall survival. Patients with treatment-resistant conditions may experience a poorer prognosis than those responding to treatment and may require more aggressive/invasive treatments to manage conditions.

·       Critical aspects of early detection: Early detection of treatment resistance is important for ensuring that patients receive appropriate care and support. Healthcare providers should be vigilant in monitoring patients for signs of treatment resistance. And should work closely with patients to develop a personalized treatment plan that takes into account their unique medical history and needs.

Use Of Psychedelics to Help People with Treatment Resistance

Research into the use of psychedelics in the treatment of treatment-resistant mental health conditions is still in very early stages. Nonetheless, there is growing evidence to suggest that these substances may have therapeutic benefits for patients who have not responded to traditional treatments.

The main advantage of psychedelics is their ability to produce altered states of consciousness, which can lead to profound psychological experiences. This is thought to be why psychedelics have been found to be effective in treating treatment-resistant mental health conditions. For instance, research has found that psilocybin (the active ingredient in magic mushrooms) can produce rapid and significant reductions in depression and anxiety symptoms in treatment-resistant patients.

Similarly, research suggests that ketamine has rapid antidepressant effects, with some studies reporting significant improvements in depression symptoms within hours of administration. Ketamine also has potential benefits for other treatment-resistant mental health conditions, including anxiety, bipolar disorder and PTSD.

However, it is important to note that the use of psychedelic drugs in a therapeutic context is highly regulated and restricted in many countries.

Despite these risks, the use of psychedelics in the treatment of treatment-resistant mental health conditions is gaining increasing attention from researchers and clinicians. In fact, in 2018, the *American Food and Drug Administration (FDA)* granted breakthrough therapy designation to psilocybin-assisted therapy for treatment-resistant depression, indicating that the therapy may have significant advantages over existing treatments.


There is still much to learn about the therapeutic potential of psychedelics in the treatment of mental health conditions. However, recent research suggests that these substances may hold promise for patients who have not responded to traditional treatments. Further, research is needed to fully understand the risks and benefits of these substances.

The Economic Impact of Cannabis in Pro Sports

The United States’ pro sports leagues have been notoriously strict when it comes to cannabis use by athletes. But recent developments suggest that attitudes are shifting.

The National Basketball Association (NBA) is reportedly set to allow players to invest in cannabis companies, as part of its new seven-year collective bargaining agreement.

The agreement, reached last weekend with the National Basketball Player Association (NBPA), is expected to remove drug testing requirements for marijuana. The news was first reported by Shams Charania of The Athletic and Stadium. Who noted the inclusion of the cannabis investment policy.

Game changer: The league’s new collective bargaining agreement will give players the ability to invest in NBA and WNBA teams, as well as promote and/or invest in sports betting and cannabis companies, sources tell  @TheAthletic @Stadium 

The NBPA has not provided any further information on the agreement. Stating on Twitter that details will be shared once a term sheet is finalized.

That being said, the decision comes after years of pressure from athletes and advocates. Who have long pointed out the therapeutic benefits of cannabis use for athletes. Particularly those dealing with pain and anxiety related to injuries.

While other leagues have allowed CBD sponsorships, the NBA’s policy appears to be more progressive. The league suspended cannabis testing in 2020 during the coronavirus pandemic. And has decided not to reinstate the tests for the upcoming season.

Instead, the league will reach out to players who exhibit signs of problematic dependency. The new policy is part of a tentative agreement on a new Collective Bargaining Agreement, pending ratification by players and team governors.

By allowing players to promote and invest in cannabis companies, pro sports leagues are opening up a new market for the cannabis industry. This move could lead to increased investment and growth opportunities.

However, it’s important to note that cannabis use is still illegal under federal law in the United States. Meaning players who use cannabis could still face legal consequences outside of the league.


Let’s get your project started!

Fill out the simple form to the right and we’ll be in touch ASAP to find out how Icaro Connect can help you achieve your business goals.